Clinical

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years in terms of clinical practice change?

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What updates to KDIGO will likely need to be made in view of these novel therapies being approved? How should payers and health systems think differently about treating this disease?

Immunotherapies are transforming treatment and improving outcomes for patients with advanced cSCC, according to Todd Schlesinger, MD.

The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts.

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide.

Bidisha Mandal, PhD, concluded her conversation with AJMC by emphasizing the need for policy support and further research to maximize telehealth's impact.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts weigh neoadjuvant vs adjuvant immunotherapy in resectable lung cancer, balancing PD‑L1, pCR, surgery timing, and toxicity.

These new data highlight CRC screening gaps, as well as disparities in incidence and survival.

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Food-insecure adults have fewer annual health visits but rely more on telehealth for primary care, lowering per-visit costs, says Bidisha Mandal, PhD.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

Investigators in China touted durable responses seen in a phase 2 study of the CAR T-cell therapy relma-cel, which has a similar mechanism of action as liso-cel. At present, there are no approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma in China.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.

Meta-analysis links obstructive sleep apnea to early kidney injury markers, especially in severe OSA and hypertension, highlighting need for renal monitoring.

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks transparency, which may lower uptake.

In Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, our panel delves into the following critical questions: What strategies can clinicians use to advocate for access or navigate step edits? How might real-world data and ongoing registries (like RaDaR) support broader adoption and payer confidence?

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the following questions: What barriers exist to real-world use, particularly around payer policies or access? Many plans require a systemic steroid step-edit; why might this be inappropriate for IgAN?

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Azathioprine use in organ transplant recipients increases the risk of squamous cell, but not basal cell, carcinoma.